Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MAX-10181 |
Synonyms | |
Therapy Description |
MAX-10181 is a PD-L1 (CD274) small molecule inhibitor that may lead to inhibition of tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr LB-018). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MAX-10181 | MAX10181|MAX 10181 | Immune Checkpoint Inhibitor 147 PD-L1 Inhibitor 13 | MAX-10181 is a PD-L1 (CD274) small molecule inhibitor that may lead to inhibition of tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr LB-018). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04122339 | Phase I | MAX-10181 | MAX-10181 Given Orally to Patients With Advanced Solid Tumor | Unknown status | AUS | 0 |